The experience of Pear Therapeutics, Inc. – prior to its collapse – provides insight into reimbursement strategies that may be effective for others in the space, but public and private payors also note some stark realities facing prescription digital therapeutic (PDT) companies in 2023.
‘It’s Not Going To Happen Overnight’: Payors On Pear Fallout And Digital Therapeutic Coverage Prospects
Public and private payors at the Digital Therapeutics Alliance’s 2023 Inaugural Summit weighed in on the coverage environment for prescription digital therapeutics post-Pear Therapeutics and strategic moves companies can make to position themselves advantageously.
